Cargando…
Targeting TL1A/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13/IL4Rα in Muco-Secretory Fibrotic Disorders
Mucus secretion is an important feature of asthma that highly correlates with morbidity. Current therapies, including administration of mucolytics and anti-inflammatory drugs, show limited effectiveness and durability, underscoring the need for novel effective and longer lasting therapeutic approach...
Autores principales: | Steele, Hope, Sachen, Kacey, McKnight, Andrew J., Soloff, Rachel, Herro, Rana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299868/ https://www.ncbi.nlm.nih.gov/pubmed/34305924 http://dx.doi.org/10.3389/fimmu.2021.692127 |
Ejemplares similares
-
Penicillin in Muco-Purulent Conjunctivitis
por: Puttanna, S. T.
Publicado: (1951) -
Treatment of Muco-Membranous Colitis
Publicado: (1904) -
Laparoscopic colostomy takedown offers advantages over traditional surgery
por: Schmelzer, Thomas M, et al.
Publicado: (2006) -
The Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms
por: Li, Yanxia, et al.
Publicado: (2022) -
The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes
por: Tapia, Victor S., et al.
Publicado: (2019)